WO2015178380A1 - N-アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム - Google Patents
N-アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム Download PDFInfo
- Publication number
- WO2015178380A1 WO2015178380A1 PCT/JP2015/064344 JP2015064344W WO2015178380A1 WO 2015178380 A1 WO2015178380 A1 WO 2015178380A1 JP 2015064344 W JP2015064344 W JP 2015064344W WO 2015178380 A1 WO2015178380 A1 WO 2015178380A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sugar chain
- acetylglucosamine sugar
- drug
- containing compound
- acetylglucosamine
- Prior art date
Links
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 title claims abstract description 124
- 150000001875 compounds Chemical class 0.000 title claims abstract description 123
- 229950006780 n-acetylglucosamine Drugs 0.000 title claims abstract description 115
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 title claims abstract description 111
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 title claims abstract description 111
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 229940079593 drug Drugs 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000012377 drug delivery Methods 0.000 title claims abstract description 18
- 239000002245 particle Substances 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000002872 contrast media Substances 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 229920000642 polymer Polymers 0.000 claims description 9
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical group OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- -1 biotin compound Chemical class 0.000 claims description 5
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 30
- 230000027455 binding Effects 0.000 abstract description 19
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 102000004169 proteins and genes Human genes 0.000 abstract description 18
- 102100036912 Desmin Human genes 0.000 abstract description 9
- 108010044052 Desmin Proteins 0.000 abstract description 9
- 210000005045 desmin Anatomy 0.000 abstract description 8
- 230000000052 comparative effect Effects 0.000 description 22
- 102000013127 Vimentin Human genes 0.000 description 19
- 108010065472 Vimentin Proteins 0.000 description 19
- 210000005048 vimentin Anatomy 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000000178 monomer Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 12
- QLTSDROPCWIKKY-PMCTYKHCSA-N beta-D-glucosaminyl-(1->4)-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 QLTSDROPCWIKKY-PMCTYKHCSA-N 0.000 description 9
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 7
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 229910052737 gold Inorganic materials 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 230000003176 fibrotic effect Effects 0.000 description 5
- 125000001165 hydrophobic group Chemical group 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 229940093817 Convertase inhibitor Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 239000004626 polylactic acid Substances 0.000 description 4
- 230000000379 polymerizing effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012986 chain transfer agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BVWUEIUNONATML-UHFFFAOYSA-N n-benzylethenamine Chemical compound C=CNCC1=CC=CC=C1 BVWUEIUNONATML-UHFFFAOYSA-N 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 230000002966 stenotic effect Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- FYXAVEIRUNEOSG-UHFFFAOYSA-N 4-benzyl-5-ethenylisoindole-1,3-dione Chemical compound C=CC1=CC=C2C(=O)NC(=O)C2=C1CC1=CC=CC=C1 FYXAVEIRUNEOSG-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical group O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 150000002251 gadolinium compounds Chemical class 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F12/02—Monomers containing only one unsaturated aliphatic radical
- C08F12/04—Monomers containing only one unsaturated aliphatic radical containing one ring
- C08F12/14—Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing heteroatoms
- C08F12/26—Nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F12/02—Monomers containing only one unsaturated aliphatic radical
- C08F12/32—Monomers containing only one unsaturated aliphatic radical containing two or more rings
Definitions
- the present invention relates to a compound containing an N-acetylglucosamine sugar chain group, a carrier compound for drug transport, a preparation, and a drug transport system, and more specifically, easily reaches a cell / site where vimentin or a desmin protein is exposed, and , N-acetylglucosamine sugar chain group-containing compound having excellent binding property with N-acetylglucosamine sugar chain recognition protein, carrier compound for drug transport comprising the compound, formulation using the carrier compound, and drug transport system It is.
- an intervention treatment is performed to insert a balloon or a stent into the blood vessel to push the stenotic site.
- the balloon and the stent are rubbed at the stenosis portion, and the vascular endothelial cells are peeled off to cause injury.
- inflammation is caused in the blood vessels, or intimal thickening due to abnormal proliferation of smooth muscle cells and cardiomyocytes under the injured site or new thrombus formation is caused to narrow the blood vessels again. Therefore, it is a complicated and heavy burden on the patient by inserting a coil coated with a drug sustained-release preparation for anti-inflammation, thickening prevention, thrombus prevention, etc. to prevent restenosis. Must be given.
- fibrotic disorders such as a fibrotic disorder in which excessive fibrosis causes pathological disorder and tissue dysfunction are caused by accumulation of fibrous tissue in an abnormal form in the tissue.
- This fibrotic tissue can also result from surgical processes, trauma, or other non-wound processes such as cirrhosis, liver fibrosis, glomerulonephritis, pulmonary fibrosis, scleroderma, myocardial fibrosis, post-myocardial infarction Chronic, such as central fibrosis after seizures or neurodegenerative disorders (such as Alzheimer's disease), proliferative vitreoretinopathy (PVR), restenosis (such as after angioplasty) and arthritis Also mentioned.
- neurodegenerative disorders such as Alzheimer's disease
- PVR proliferative vitreoretinopathy
- restenosis such as after angioplasty
- arthritis also mentioned.
- Non-patent document 1 describes a complex of a neoglycoprotein, which is a sugar chain-introduced drug delivery material, and a liposome as a drug transport system
- non-patent document 2 is a gene transport agent specific for hepatocytes.
- a complex of polyethyleneimine and arabinogalactan is described. However, they do not have specific binding properties to the heart or blood vessel injury site.
- a carrier compound for transporting a drug having a first region having an affinity for a lipid membrane having a drug inside and a second region bound to the first region and containing a self-magnetic organic molecule is used.
- Drug delivery systems and the like have been proposed.
- N-acetylglucosamines are used as drug transport agents, but it is difficult for vimentin and desmin-based N-acetylglucosamine-recognizing proteins to reach exposed cells / sites, and drugs reach Even so, it was not yet satisfactory in terms of performance, such as not binding to or difficult to bind to the N-acetylglucosamine sugar chain recognition protein.
- an object of the present invention is to provide an N-acetylglucosamine sugar chain group-containing compound that easily reaches a cell or site where vimentin or a desmin-based protein is exposed and has excellent binding properties to an N-acetylglucosamine sugar chain recognition protein, It is to provide a drug transport carrier compound comprising the compound, a preparation using the drug transport carrier compound, and a drug transport system.
- the present inventors have found that the above problems can be solved by adjusting the weight average molecular weight of the compound having an N-acetylglucosamine sugar chain group to a specific range.
- the present invention has been completed.
- the N-acetylglucosamine sugar chain group-containing compound of the present invention is characterized by having a weight average molecular weight in the range of 15,000 to 100,000.
- the N-acetylglucosamine sugar chain-containing compound of the present invention is preferably a polymer.
- the N-acetylglucosamine sugar chain-containing compound of the present invention preferably has 27 to 175 N-acetylglucosamine sugar chain groups per molecule.
- the N-acetylglucosamine sugar chain-containing compound of the present invention is preferably a biotin compound.
- the N-acetylglucosamine sugar chain group-containing compound of the present invention preferably has 3-mercaptopropionic acid bonded to the terminal.
- the carrier compound for drug transport of the present invention is characterized by comprising the N-acetylglucosamine sugar chain group-containing compound.
- the carrier compound for drug transport carries at least one drug among a therapeutic agent, a fluorescent agent and a contrast agent, and the N-acetylglucosamine sugar chain group is exposed on the surface. It is characterized by this.
- the carrier compound for transporting a drug of the present invention is characterized in that the N-acetylglucosamine sugar chain group is a colloidal particle exposed on the surface.
- the preparation of the present invention is characterized in that the colloidal particles of the carrier compound for drug transport contain at least one drug among therapeutic agents, fluorescent agents and contrast agents.
- the drug delivery system includes an N-acetylglucosamine sugar exposed on the surface by binding the N-acetylglucosamine sugar chain group-containing compound to the surface of at least one drug among a therapeutic agent, a fluorescent agent and a contrast agent.
- the drug is guided to a target affected area by a chain group.
- the colloidal particles having the N-acetylglucosamine sugar chain group-containing compound bound to the surface contain at least one drug among a therapeutic agent, a fluorescent agent and a contrast agent,
- the drug in the colloidal particles is guided to the target affected area by the exposed N-acetylglucosamine sugar chain group.
- an N-acetylglucosamine sugar chain-containing compound that easily reaches vimentin or a desmin-based protein / exposed cell and has excellent binding properties to an N-acetylglucosamine sugar chain recognition protein
- a drug transport carrier compound comprising a compound, a preparation using the drug transport carrier compound, and a drug transport system can be provided.
- 3 is a sensorgram for evaluating the binding between the N-acetylglucosamine sugar chain group-containing compound of Comparative Example 2 and vimentin immobilized on the gold surface.
- 10 is a sensorgram for evaluating the binding between the N-acetylglucosamine sugar chain group-containing compound of Comparative Example 3 and vimentin immobilized on the gold surface.
- 2 is a sensorgram for evaluating the binding between the N-acetylglucosamine sugar chain group-containing compound of Example 1 and vimentin immobilized on a gold surface.
- 6 is a sensorgram for evaluating the binding between the N-acetylglucosamine sugar chain group-containing compound of Comparative Example 4 and vimentin immobilized on the gold surface.
- 6 is a graph showing the staining degree of HeLa cells with the N-acetylglucosamine sugar chain group-containing compound of Comparative Example 1 labeled with FITC.
- 6 is a graph showing the staining degree of HeLa cells with the N-acetylglucosamine sugar chain group-containing compound of Comparative Example 2 labeled with FITC.
- 6 is a graph showing the staining degree of HeLa cells with the N-acetylglucosamine sugar chain group-containing compound of Comparative Example 3 labeled with FITC.
- 2 is a graph showing the staining degree of HeLa cells with the N-acetylglucosamine sugar chain group-containing compound of Example 1 labeled with FITC.
- 6 is a graph showing the staining degree of HeLa cells with the N-acetylglucosamine sugar chain group-containing compound of Comparative Example 4 labeled with FITC.
- the N-acetylglucosamine sugar chain-containing compound of the present invention is a compound having a weight average molecular weight in the range of 15,000 to 100,000 and having an N-acetylglucosamine sugar chain group.
- the weight average molecular weight is preferably in the range of 16,000 to 50,000, more preferably in the range of 16,500 to 40,000, from the viewpoints of synthesis properties, yield, and drug reachability, and 17,000. More preferably, it is in the range of ⁇ 30,000.
- a vinyl resin in which chitobiose is bonded at the N-acetylglucosamine terminal is used (for example, Example 1 of Patent Document 2), and its weight average molecular weight was about 120,000.
- a colloid of a drug transporter obtained by binding an N-acetylglucosamine sugar chain group-containing compound (molecular weight of about 700) obtained by binding chitobiose and biotin to a carrier has been used (for example, Patent Document 3).
- Example 13 ).
- examples of the N-acetylglucosamine sugar chain group include N-acetylglucosamine groups and chitopolyose groups in which 2 to 6 N-acetylglucosamine groups are bonded, that is, chitobiose.
- groups chitotriose group, chitotetraose group, chitopentaose group and chitohexaose group.
- N-acetylglucosamine group and chitobiose group are preferable, and chitobiose group is more preferable.
- N-acetylglucosamine sugar chain group examples include a chemical formula of a chitobiose group, but the present invention is not limited to this.
- the N-acetylglucosamine sugar chain-containing compound of the present invention preferably has 27 to 175, more preferably 29 to 88, and more preferably 30 to 70 N-acetylglucosamine sugar chain groups per molecule. More preferably, it is more preferably 30-50.
- the N-acetylglucosamine sugar chain-containing compound of the present invention has an N-acetylglucosamine sugar chain group in order to act on an N-acetylglucosamine recognition protein such as vimentin and desmin, and is appropriately selected according to the purpose On the other hand, it can be obtained by introducing an N-acetylglucosamine sugar chain group.
- the compound of the present invention is more preferably a polymer obtained by polymerizing a monomer having an N-acetylglucosamine sugar chain group, or a compound in which N-acetylglucosamine is bound to a polymer compound such as a polymer.
- the compound of the present invention is preferably a polymer.
- the N-acetylglucosamine sugar chain group-containing compound of the present invention may have a hydrophobic group from the viewpoint of adsorptivity with a carrier.
- the method for producing the N-acetylglucosamine sugar chain group-containing compound is not particularly limited.
- a method for producing a polymer obtained by polymerizing a monomer having the N-acetylglucosamine sugar chain group a compound having a hydrophobic group such as a styrene compound is bonded to the reducing end of the N-acetylglucosamine sugar chain.
- Examples include a method of polymerizing monomers.
- the method for binding the N-acetylglucosamine sugar chain to the compound is not particularly limited.
- the reductive amination method is performed by combining the amino group of the compound having an amino group and the reducing end of the N-acetylglucosamine sugar chain. Can be combined.
- the hydroxy group of the N-acetylglucosamine sugar chain is substituted with a carboxyl group, and the amino group of the compound having an amino group is obtained by 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDC) coupling method or the like. It may be combined.
- EDC 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide
- the method for polymerizing the monomer is not particularly limited, and can be obtained by, for example, a living radical polymerization method or a polymerization method using a chain transfer agent.
- a monomer is prepared by mixing chitobiose as an N-acetylglucosamine sugar chain and vinylbenzyl phthalimide as a compound having a hydrophobic group in a molar ratio of 1: 1, such as DMF, DMSO or water.
- Poly [Np-vinylbenzyl-O-2-acetoamid-2-deoxy- ⁇ -D-glucopyranosyl- (1 ⁇ 4) -2-acetoamide-2-deoxy- ⁇ -D-gluconamide ] (PVGlcNAc) can be obtained.
- a polymer with a controlled molecular weight can be produced by changing the mixing ratio of a chain transfer agent such as mercaptopropionic acid to a monomer during polymerization.
- the N-acetylglucosamine sugar chain group-containing compound of the present invention may be an N-acetylglucosamine sugar chain group-containing biotin compound.
- An N-acetylglucosamine sugar chain group-containing biotin compound can be produced by treating an N-acetylglucosamine sugar chain group-containing compound with a weak acid to produce an aldehyde group and reacting biotin having a hydrazine group. .
- the drug transport carrier compound of the present invention comprises the N-acetylglucosamine sugar chain group-containing compound of the present invention.
- the carrier compound for drug transport of the present invention may be composed only of the N-acetylglucosamine group-containing compound, but other materials such as carriers used for drug transport, for example, the N- What combined the acetylglucosamine sugar chain group containing compound may be used.
- colloidal particles examples include gold or platinum, silver, magnetic materials, ceramic or other metal or inorganic particles, polyethylene glycol, polystyrene, acrylic resin, polylactic acid, polycaprolactone, polyhydroxyalkanoate, polyglycolic acid, modified polyvinyl Synthetic or natural product-derived resin particles such as alcohol, casein, modified starch, cellulose, and protein, and liposomes may be mentioned.
- the method for binding the N-acetylglucosamine sugar chain group-containing compound to the surface of the colloidal particles is not particularly limited.
- the colloidal particles when they are gold particles, they can be bonded by introducing a thiol group into the N-acetylglucosamine sugar chain group-containing compound and covalently bonding to the gold colloid surface.
- the solution in which the N-acetylglucosamine group-containing compound is dissolved is mixed with polylactic acid, and the surface of the polylactic acid particles is coated with the N-acetylglucosamine sugar chain group-containing compound. it can.
- liposomes they can be bound by coating the liposome surface with an N-acetylglucosamine sugar chain-containing compound into which an alkyl group has been introduced.
- the particle diameter of the colloidal particles is preferably in the range of 5 to 800 nm in mass average particle diameter. If the particle size is less than 5 nm, it is difficult to bind the N-acetylglucosamine group-containing compound, and particles to which no N-acetylglucosamine group has been added are rapidly excreted in the living body, which is not preferable. Moreover, when the particle size exceeds 800 nm, it is not preferable because it is excluded as a foreign substance in the living body by phagocytic cells. From the viewpoint of N-acetylglucosamine group loading on the particle surface and drug transportability, the thickness is preferably 7 to 500 nm, particularly preferably 10 to 300 nm. By controlling the particle size within this range, it is possible to selectively and efficiently reach only cells or sites such as gaps formed between cells at the site of vascular injury or smooth muscle cells exposed in the blood vessel, and taken into cells and sites. It will be easier.
- the carrier compound for drug transport carries at least one drug among a therapeutic agent, a fluorescent agent and a contrast agent, and the N-acetylglucosamine sugar chain group is exposed on the surface. It is characterized by this.
- the carrier compound for drug transport is a colloidal particle having an N-acetylglucosamine sugar chain group exposed on the surface, and the therapeutic agent, the fluorescent agent are contained in the colloidal particle. And at least one kind of drug among the contrast agents.
- the N-acetylglucosamine sugar chain group of the carrier compound for drug transport and the N-acetylglucosamine sugar chain recognition protein interact and attract each other, and adhere to or enter this cell. Thereafter, the drug is exuded and released from the preparation, absorbed by the cells, fluorescent or contrasted, and exhibiting a medicinal effect.
- fluorescent agent examples include fluorescein isothiocyanate (FITC), and dye for live cell staining, Calcein-AM (manufactured by Doujin Chemical Laboratory Co., Ltd .; trade name).
- contrast agent examples include gadolinium compounds for nuclear magnetic resonance imaging.
- therapeutic agents include vascular endothelial cell proliferation promoters, vascular smooth muscle cell proliferation inhibitors, anti-inflammatory agents, anticancer agents, and anti-rheumatic agents.
- the drug delivery system of the present invention is obtained by binding the compound of the present invention to the surface of at least one of a fluorescent agent, a contrast agent and a therapeutic agent, and the N-acetylglucosamine sugar chain group exposed on the surface. It is characterized in that the drug is guided to the affected area.
- at least one of a therapeutic agent, a fluorescent agent and a contrast agent is contained in colloidal particles having the compound of the present invention bound to the surface, and exposed to the surface. It is characterized in that the drug in the colloidal particles is guided to a target affected area by an N-acetylglucosamine sugar chain group.
- the N-acetylglucosamine sugar chain group-containing compound, the drug transport carrier compound, the drug using the drug transport carrier compound, and the drug transport system of the present invention are more desirable than the conventional drug transport system. Because it can reach the cells / sites (vimestin and desmin-type protein exposed cells / sites), it can be efficiently used in a smaller amount than the conventional drug delivery system. As a result, it is possible to obtain a high drug effect. Therefore, the N-acetylglucosamine sugar chain group-containing compound, the drug transport carrier compound, the preparation, and the drug transport system of the present invention are effective in the medical field, particularly in examination, diagnosis, and treatment.
- Example 1 Preparation of N-acetylglucosamine sugar chain group-containing compound (PV-GlcNAc; weight average molecular weight 17,000)] 0.1BN of the monomer obtained above was mixed with 0.000185 mmol MPA and AIBN in such an amount that the final concentration was 0.5%, and dissolved in 500 ⁇ L of DMSO. This solution was polymerized by incubation in an oil bath at 65 ° C. for 18 hours. After 18 hours, it was dissolved in water and dialyzed overnight. After dialysis, lyophilization was performed.
- PV-GlcNAc weight average molecular weight 17,000
- vimentin N-acetylglucosamine sugar chain recognition protein
- the recombinant protein of vimentin's N-acetylglucosamine binding domain is immobilized on a sensor chip, and NIA is used with BIACORE-J manufactured by GE Healthcare.
- BIACORE-J BIACORE-J manufactured by GE Healthcare.
- the interaction of acetylglucosamine sugar chain-containing compounds with vimentin was investigated by surface plasmon resonance analysis. From the obtained sensorgram, the degree of interaction was relatively judged by observing the sensorgram and comparing the maximum value of the sensorgram visually.
- FIGS. 1 to 4 The sensorgram results of the N-acetylglucosamine sugar chain-containing compounds of Comparative Example 2, Comparative Example 3, Example 1 and Comparative Example 4 are shown in FIGS. 1 to 4 (for Comparative Example 3, 0.5 ⁇ g / ml). Is not measured).
- the vertical axis represents the resonance unit, and the horizontal axis represents time (seconds).
- the vertical axis represents the number of cells, and the horizontal axis represents the fluorescence intensity.
- the fill-in histogram shows FITC-PV-MA acting as a negative control, and the fill-out histogram shows a HeLa cell population in response to FITC-PV-GlcNAc.
- the N-acetylglucosamine sugar chain group-containing compounds of the examples are excellent in interaction with the N-acetylglucosamine sugar chain recognition protein and easily reach the N-acetylglucosamine sugar chain recognition protein in HeLa cells. I understand that.
- the drug transporter carrier using the N-acetylglucosamine sugar chain group-containing compound of the present invention it is possible to selectively allow the drug to reach desired cells and sites. Recognize. Further, it can be seen that the drug delivery system using the compound of the present invention enables the drug to efficiently reach cells / parts other than the desired cells / parts.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Ceramic Engineering (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明の薬剤輸送用キャリアー化合物は、本発明のN-アセチルグルコサミン糖鎖基含有化合物からなるものである。本発明の薬剤輸送用キャリアー化合物は、前記N-アセチルグルコサミン基含有化合物のみから構成されてもよいが、薬剤輸送に用いられる担体等の他の材料、例えば、コロイド状粒子の表面に前記N-アセチルグルコサミン糖鎖基含有化合物を結合させたものであってもよい。コロイド状粒子としては、例えば金、白金、銀、磁性体、セラミックなどの金属又は無機粒子、ポリエチレングリコール、ポリスチレン、アクリル系樹脂、ポリ乳酸、ポリカプロラクトン、ポリヒドロキシアルカノエート、ポリグリコール酸、変性ポリビニルアルコール、カゼイン、変性澱粉及びセルロース、プロテインなどの合成又は天然物由来樹脂粒子、リポソームなどが挙げられる。このコロイド状粒子の表面にN-アセチルグルコサミン糖鎖基含有化合物を結合させる方法は特に限定されない。例えば、コロイド状粒子が金粒子の場合、N-アセチルグルコサミン糖鎖基含有化合物にチオール基を導入し、金コロイド表面への共有結合を行うことにより結合させることができる。また、ポリ乳酸の場合、N-アセチルグルコサミン基含有化合物を溶解させた溶液をポリ乳酸と混合し、ポリ乳酸粒子の表面にN-アセチルグルコサミン糖鎖基含有化合物をコーティングすることにより結合させることができる。さらにリポソームの場合は、N-アセチルグルコサミン糖鎖基含有化合物にアルキル基を導入したものをリポソーム表面にコーティングすることにより結合させることができる。
本発明の製剤は、前記薬剤輸送用キャリアー化合物が、治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤を担持し、かつ、前記N-アセチルグルコサミン糖鎖基が表面に露出していることを特徴とするものである。また、本発明の他の製剤は、前記薬剤輸送用キャリアー化合物がN-アセチルグルコサミン糖鎖基が表面に露出しているコロイド状粒子であって、前記コロイド状粒子中に、治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤が含有されていることを特徴とするものである。これらの本発明の製剤は投与されると、ビメンチンやデスミン等のN-アセチルグルコサミン糖鎖認識タンパク質を露出している細胞・部位に血液循環により到達する。すると薬剤輸送用キャリアー化合物のN-アセチルグルコサミン糖鎖基と、N-アセチルグルコサミン糖鎖認識タンパク質とが相互作用して引き寄せあい、この細胞に付着したり侵入したりする。その後、前記薬剤が製剤中から滲出して放出され、細胞に吸収され、蛍光させたり造影させたり薬効を発現するものである。
本発明の薬剤輸送システムは、蛍光剤、造影剤および治療剤のうち少なくとも1種の薬剤の表面に、本発明の化合物を結合させて、表面に露出したN-アセチルグルコサミン糖鎖基によって、前記薬剤を患部領域に誘導することを特徴とするものである。また、本発明の他の薬剤輸送システムは、表面に本発明の化合物を結合させたコロイド状粒子中に治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤を含有させ、表面に露出したN-アセチルグルコサミン糖鎖基によって前記コロイド状粒子中の前記薬剤を目的の患部領域に誘導することを特徴とするものである。
キトビオース(0.5g)をメタノール(20mL)に溶解して、1.425gのヨウ素を添加した。4%KOHをヨウ素の茶色が消えるまで滴下して加えた。その後、ジエチルエーテルで再結晶させた後、結晶物を水に溶解してイオン交換樹脂(アンバーライトIR-120)でキトビオン酸を精製した。ビニルベンジルアミンにWSC(水溶性カルボジイミド)を用いてキトビオン酸を縮合した。作製されたモノマーはクロロホルムで沈殿精製した。その後、沈殿物を水に溶解して凍結乾燥を行った。
上記で得たモノマー 0.185mmolに、0.00185mmol 3-メルカプトプロピオン酸(MPA)、及び、終濃度が0.5%になる量でアゾビスイソブチロニトリル(AIBN)を混合し、500μLのジメチルスルホキシド(DMSO)に溶解させた。この溶液を65℃のオイルバス中で18時間インキュベーションを行い重合した。18時間後、水に溶解させ一昼夜透析を行った。透析後、凍結乾燥を行った。
上記で得たモノマー 0.185mmolに、0.0009mmol MPA、及び、終濃度が0.5%になる量でAIBNを混合し、500μLのDMSOに溶解させた。この溶液を65℃のオイルバス中で18時間インキュベーションを行い重合した。18時間後、水に溶解させ一昼夜透析を行った。透析後、凍結乾燥を行った。
上記で得たモノマー 0.185mmolに、0.00037mmol MPA、及び、終濃度が0.5%になる量でAIBNを混合し、500μLのDMSOに溶解させた。この溶液を65℃のオイルバス中で18時間インキュベーションを行い重合した。18時間後、水に溶解させ一昼夜透析を行った。透析後、凍結乾燥を行った。
上記で得たモノマー 0.185mmolに、0.000185mmol MPA、及び、終濃度が0.5%になる量でAIBNを混合し、500μLのDMSOに溶解させた。この溶液を65℃のオイルバス中で18時間インキュベーションを行い重合した。18時間後、水に溶解させ一昼夜透析を行った。透析後、凍結乾燥を行った。
上記で得たモノマー 0.185mmolに、終濃度が0.5%になる量でAIBNを混合し、500μLのDMSOに溶解させた。この溶液を65℃のオイルバス中で18時間インキュベーションを行い重合した。18時間後、水に溶解させ一昼夜透析を行った。透析後、凍結乾燥を行った
ビメンチンのN-アセチルグルコサミン結合ドメインの組み替えタンパク質をセンサーチップに固定化して、GEヘルスケア社製BIACORE-Jを用いて、N-アセチルグルコサミン糖鎖基含有化合物のビメンチンへの相互作用を表面プラズモン共鳴解析によって検討した。得られたセンサーグラムから相互作用の程度を、センサーグラムを観察し、目視により、センサーグラムの最大の値を比較して相対的に判断した。
N-アセチルグルコサミン糖鎖基含有化合物の5種類の濃度系列(0.5μg/ml、1μg/ml、2.5μg/ml、5μg/ml、10μg/mlの5種類)を用意して、金表面に固定化したビメンチンと用意したN-アセチルグルコサミン糖鎖基含有化合物との結合(分子間相互作用)をGEヘルスケア社製BIACORE-Jで検討した。各濃度のセンサーグラムの結果から、N-アセチルグルコサミン糖鎖基含有化合物の解離定数を算出した。比較例2、比較例3、実施例1および比較例4のN-アセチルグルコサミン糖鎖含有化合物のセンサーグラムの結果をそれぞれ、図1~4に示す(比較例3については、0.5μg/mlは未測定)。縦軸はレゾナンスユニットを、横軸は時間(秒)を表す。これらの図は、各濃度の化合物のビメンチンに対する反応性を示したものである。高濃度になるにつれて反応性が上昇している。N-アセチルグルコサミン糖鎖基含有化合物をビメンチンに反応させてから120秒(比較例は60秒)まではビメンチンとの結合を示し120秒(比較例は60秒)以降は、ビメンチンからのN-アセチルグルコサミン糖鎖基含有化合物の解離を示している。これらの反応経過から解離定数を算出した。尚、比較例2については、0.5μg/mlはほとんど変化せず、解離定数の計算から外した。
5×105cells/mLのHeLa細胞懸濁液500μLにFITCラベルしたN-アセチルグルコサミン糖鎖基含有化合物(FITC-PV-GlcNAc)を4μg/mLで反応させた。反応は、4℃で30分行った。その後、遠心を行いPBSに再懸濁して、その細胞染色をフローサイトメーター(GUAVA easyCyte、ミリポア社製)でフローサイトメトリーを行い、FITC-PV-GlcNAcによるHeLa細胞の染色を検討した。比較例1、比較例2、比較例3、実施例1および比較例4のN-アセチルグルコサミン糖鎖含有化合物のフローサイトメトリーの結果をそれぞれ、図5~9に示す。縦軸は細胞数、横軸は蛍光強度を表す。中塗りつぶしのヒストグラムは、ネガティブコントロールとしてFITC-PV-MAを作用させたものであり、中抜けのヒストグラムはFITC-PV-GlcNAcに反応したHeLa細胞集団を示している。
高速GPC装置(東ソー社製、HLC-8220GPC)を用いて、次の条件で各材料の重量平均分子量を測定した。カラムは、TSKgel G6000PWxL-CP+G5000PWxL-CP+3000PWxL-CPを用いて溶離液は、200mM 硝酸ナトリウム/アセトニトリル=80/20で行った。流量は1mL/min、検出器はRI検出器、カラム温度は40℃で行った。分子量の標準曲線はプルランで実施した。
Claims (11)
- 重量平均分子量が15,000~100,000の範囲であることを特徴とするN-アセチルグルコサミン糖鎖基含有化合物。
- ポリマーであることを特徴とする請求項1記載のN-アセチルグルコサミン糖鎖基含有化合物。
- 前記N-アセチルグルコサミン糖鎖基を1分子当たり27~175個有することを特徴とする請求項1記載のN-アセチルグルコサミン糖鎖基含有化合物。
- ビオチン化合物であることを特徴とする請求項1記載のN-アセチルグルコサミン糖鎖基含有化合物。
- 末端に3-メルカプトプロピオン酸が結合されていることを特徴とする請求項2記載のN-アセチルグルコサミン糖鎖基含有化合物。
- 請求項1~5のいずれか一項記載のN-アセチルグルコサミン糖鎖基含有化合物からなることを特徴とする薬剤輸送用キャリアー化合物。
- 前記N-アセチルグルコサミン糖鎖基が表面に露出しているコロイド状粒子であることを特徴とする請求項6記載の薬剤輸送用キャリアー化合物。
- 請求項6記載の薬剤輸送用キャリアー化合物が、治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤を担持し、かつ、前記N-アセチルグルコサミン糖鎖基が表面に露出していることを特徴とする製剤。
- 請求項7記載の薬剤輸送用キャリアー化合物の前記コロイド状粒子中に、治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤が含有されていることを特徴とする製剤。
- 治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤の表面に請求項1~5のいずれか一項記載のN-アセチルグルコサミン糖鎖基含有化合物を結合させて、表面に露出したN-アセチルグルコサミン糖鎖基によって前記薬剤を目的の患部領域に誘導することを特徴とする薬剤輸送システム。
- 表面に請求項1~5のいずれか一項記載のN-アセチルグルコサミン糖鎖基含有化合物を結合させたコロイド状粒子中に治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤を含有させ、表面に露出したN-アセチルグルコサミン糖鎖基によって前記コロイド状粒子中の前記薬剤を目的の患部領域に誘導することを特徴とする薬剤輸送システム。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/312,507 US10471158B2 (en) | 2014-05-21 | 2015-05-19 | N-acetylglucosamine sugar chain group-containing compound, carrier compound for drug delivery, drug preparation, and drug delivery system |
EP15796230.9A EP3147300B1 (en) | 2014-05-21 | 2015-05-19 | N-acetylglucosamine sugar chain group-containing polymer, carrier compound for drug delivery, drug preparation, and drug delivery system |
CN201580026100.4A CN106459259B (zh) | 2014-05-21 | 2015-05-19 | 含n-乙酰葡糖胺糖链基化合物、药剂输送用载体化合物、制剂、及药剂输送系统 |
KR1020167035868A KR102170249B1 (ko) | 2014-05-21 | 2015-05-19 | N-아세틸글루코사민 당쇄기 함유 화합물, 약제 수송용 캐리어 화합물, 제제, 및 약제 수송 시스템 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014104811A JP6472608B2 (ja) | 2014-05-21 | 2014-05-21 | N−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム |
JP2014-104811 | 2014-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015178380A1 true WO2015178380A1 (ja) | 2015-11-26 |
Family
ID=54554048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/064344 WO2015178380A1 (ja) | 2014-05-21 | 2015-05-19 | N-アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム |
Country Status (7)
Country | Link |
---|---|
US (1) | US10471158B2 (ja) |
EP (1) | EP3147300B1 (ja) |
JP (1) | JP6472608B2 (ja) |
KR (1) | KR102170249B1 (ja) |
CN (1) | CN106459259B (ja) |
TW (1) | TWI723951B (ja) |
WO (1) | WO2015178380A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0347802A (ja) * | 1989-04-20 | 1991-02-28 | Mitsui Toatsu Chem Inc | N―アセチルキトオリゴ糖鎖を有するスチレン誘導体及びその製造方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206318A (en) * | 1989-04-20 | 1993-04-27 | Mitsui Toatsu Chemicals, Inc. | Styrene derivatives having N-acetylchito-oligosaccharide chains and method for the same |
JP3200607B2 (ja) | 1995-03-17 | 2001-08-20 | 財団法人神奈川科学技術アカデミー | 細胞診断用標識剤及びそれを用いた細胞診断システム |
EP0866802A1 (en) * | 1995-11-21 | 1998-09-30 | Novartis AG | Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds. |
US20050245735A1 (en) * | 2001-08-01 | 2005-11-03 | Shawn Defrees | Neutral glycosphingolipids and glycosyl-sphingosines and methods for isolating the same |
GB0217136D0 (en) | 2002-07-24 | 2002-09-04 | Renovo Ltd | Wound healing & treatment of fibrosis |
JP2007001923A (ja) | 2005-06-23 | 2007-01-11 | Shinshu Univ | N−アセチルグルコサミン糖鎖認識タンパク質 |
JP2009046413A (ja) | 2007-08-17 | 2009-03-05 | Shinshu Univ | N−アセチルグルコサミン糖鎖認識タンパク質 |
EP2684899B1 (en) * | 2011-03-10 | 2018-04-25 | Glytech, Inc. | Method for producing glycopeptide having sialyl sugar chain, sialyl sugar chain-added amino acid derivative to be used in same, and glycopeptide |
JP5829871B2 (ja) | 2011-09-16 | 2015-12-09 | 株式会社Ihi | リポソーム薬剤 |
-
2014
- 2014-05-21 JP JP2014104811A patent/JP6472608B2/ja active Active
-
2015
- 2015-05-19 WO PCT/JP2015/064344 patent/WO2015178380A1/ja active Application Filing
- 2015-05-19 CN CN201580026100.4A patent/CN106459259B/zh active Active
- 2015-05-19 KR KR1020167035868A patent/KR102170249B1/ko active IP Right Grant
- 2015-05-19 US US15/312,507 patent/US10471158B2/en active Active
- 2015-05-19 EP EP15796230.9A patent/EP3147300B1/en active Active
- 2015-05-21 TW TW104116215A patent/TWI723951B/zh active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0347802A (ja) * | 1989-04-20 | 1991-02-28 | Mitsui Toatsu Chem Inc | N―アセチルキトオリゴ糖鎖を有するスチレン誘導体及びその製造方法 |
Non-Patent Citations (8)
Title |
---|
HIROHIKO ISE ET AL.: "N-acetylglucosamine Gan'yu Tosa Kobunshi PV-GlcNAc o Mochiita Saibo Kino Seigyo", DAI 33 KAI THE ANNUAL MEETING OF THE JAPANESE SOCIETY FOR BIOMATERIALS YOKOSHU, 2011, pages 148, XP008185586 * |
HIROHIKO ISE ET AL.: "Vimentin and desmin possess GlcNAc-binding lectin-like properties on cell surfaces", GLYCOBIOLOGY, vol. 20, no. 7, 2010, pages 843 - 864, XP055238008, ISSN: 0959-6658 * |
KENTA KOMURA ET AL.: "Dynamic behaviors of vimentin induced by interaction with GlcNAc molecules", GLYCOBIOLOGY, vol. 22, no. 12, 2012, pages 1741 - 1759, XP055238005, ISSN: 0959-6658 * |
MAMIKO ISE ET AL.: "Targeting N-acetylglucosamine-bearing polymer-coated liposomes to vascular smooth muscle cells", J. ARTIF. ORGANS, vol. 14, no. 4, 2011, pages 301 - 309, XP019987754, ISSN: 1619-0904 * |
SATOSHI KOBAYASHI ET AL.: "Surface coating of bone marrow cells with N-acetylglucosamine for bone marrow implantation therapy", BIOMATERIALS, vol. 30, no. 4, 2009, pages 574 - 582, XP025693614, ISSN: 0142-9612 * |
See also references of EP3147300A4 * |
SHIN-ICHI ASO ET AL.: "Effective uptake of N-acetylglucosamine-conjugated liposomes by cardiomyocytes in vitro", JOURNAL OF CONTROLLED RELEASE, vol. 122, no. 2, 2007, pages 189 - 198, XP028926714, ISSN: 0168-3659 * |
SUN-JUNG KIM ET AL.: "Interactions of vimentin- or desmin-expressing liver cells with N-acetylglucosamine-bearing polymers", BIOMATERIALS, vol. 33, no. 7, 2012, pages 2154 - 2164, XP028442464, ISSN: 0142-9612 * |
Also Published As
Publication number | Publication date |
---|---|
EP3147300A1 (en) | 2017-03-29 |
US10471158B2 (en) | 2019-11-12 |
TWI723951B (zh) | 2021-04-11 |
TW201620552A (zh) | 2016-06-16 |
KR102170249B1 (ko) | 2020-10-26 |
JP2015218314A (ja) | 2015-12-07 |
EP3147300B1 (en) | 2020-06-24 |
US20170095564A1 (en) | 2017-04-06 |
EP3147300A4 (en) | 2017-12-27 |
CN106459259B (zh) | 2022-07-15 |
KR20170012369A (ko) | 2017-02-02 |
CN106459259A (zh) | 2017-02-22 |
JP6472608B2 (ja) | 2019-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mottaghitalab et al. | Targeted delivery system based on gemcitabine-loaded silk fibroin nanoparticles for lung cancer therapy | |
Luong et al. | Polyvalent folate-dendrimer-coated iron oxide theranostic nanoparticles for simultaneous magnetic resonance imaging and precise cancer cell targeting | |
Le Droumaguet et al. | Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer’s disease | |
Rajan et al. | Poly-carboxylic acids functionalized chitosan nanocarriers for controlled and targeted anti-cancer drug delivery | |
JP5914366B2 (ja) | 誘導体化超分岐ポリグリセロール類 | |
JP5597396B2 (ja) | 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤 | |
Wu et al. | In vitro drug release and biological evaluation of biomimetic polymeric micelles self-assembled from amphiphilic deoxycholic acid–phosphorylcholine–chitosan conjugate | |
Zhu et al. | Vinblastine-loaded nanoparticles with enhanced tumor-targeting efficiency and decreasing toxicity: developed by one-step molecular imprinting process | |
Deng et al. | Reactive oxygen species (ROS) responsive PEG–PCL nanoparticles with pH-controlled negative-to-positive charge reversal for intracellular delivery of doxorubicin | |
Wilms et al. | Catechol-initiated polyethers: multifunctional hydrophilic ligands for PEGylation and functionalization of metal oxide nanoparticles | |
Lee et al. | Mussel-inspired hyaluronic acid derivative nanostructures for improved tumor targeting and penetration | |
Liu et al. | Self-assembled nanospheres of folate-decorated zein for the targeted delivery of 10-hydroxycamptothecin | |
Sharma et al. | Hyaluronic acid anchored paclitaxel nanocrystals improves chemotherapeutic efficacy and inhibits lung metastasis in tumor-bearing rat model | |
Li et al. | Smart pH-responsive and high doxorubicin loading nanodiamond for in vivo selective targeting, imaging, and enhancement of anticancer therapy | |
Yang et al. | Comparison of tumor penetration of Podophyllotoxin–Carboxymethylcellulose conjugates with various chemical compositions in tumor spheroid culture and in vivo solid tumor | |
Morgese et al. | Ultrastable suspensions of polyoxazoline-functionalized ZnO single nanocrystals | |
Wang et al. | pH-sensitive and tumor-targeting nanogels based on ortho ester-modified PEG for improving the in vivo anti-tumor efficiency of doxorubicin | |
Lu et al. | Micellar nanoparticles inhibit the postoperative inflammation, recurrence and pulmonary metastasis of 4T1 breast cancer by blocking NF-κB pathway and promoting MDSCs depletion | |
Khoshnood et al. | N doped-carbon quantum dots with ultra-high quantum yield photoluminescent property conjugated with folic acid for targeted drug delivery and bioimaging applications | |
Liu et al. | High-order assembly toward polysaccharide-based complex coacervate nanodroplets capable of targeting cancer cells | |
Chen et al. | Branched polyethyleneimine modified with hyaluronic acid via a PEG spacer for targeted anticancer drug delivery | |
Zhao et al. | Robust construction of supersmall zwitterionic micelles based on hyperbranched polycarbonates mediates high tumor accumulation | |
Atrei et al. | Covalent hyaluronic-based coating of magnetite nanoparticles: Preparation, physicochemical and biological characterization | |
Li et al. | Effect of protein adsorption on cell uptake and blood clearance of methoxy poly (ethylene glycol)‐poly (caprolactone) nanoparticles | |
JP6472608B2 (ja) | N−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15796230 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15312507 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015796230 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015796230 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20167035868 Country of ref document: KR Kind code of ref document: A |